Literature DB >> 24005836

SEOM clinical guidelines for the treatment of small-cell lung cancer 2013.

M Dómine Gómez1, T Morán Bueno, A Artal Cortés, J Remon Masip, P Lianes Barragán.   

Abstract

In this updated SCLC guidelines the authors have reviewed the "SEOM recommendation" for diagnosis and treatment of patients, including consideration for elderly and unfit patients. We hope the SCLC guidelines will be useful for residents and oncology teams.

Entities:  

Mesh：

Year:  2013        PMID： 24005836     DOI： 10.1007/s12094-013-1086-1

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  28 in total

1.  Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.

Authors:  A Aupérin; R Arriagada; J P Pignon; C Le Péchoux; A Gregor; R J Stephens; P E Kristjansen; B E Johnson; H Ueoka; H Wagner; J Aisner
Journal:  N Engl J Med       Date:  1999-08-12       Impact factor: 91.245

2.  An updated meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.

Authors:  Ning Shao; Shidai Jin; Wei Zhu
Journal:  J Thorac Oncol       Date:  2012-02       Impact factor: 15.609

Review 3.  Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer.

Authors:  Daniel B Fried; David E Morris; Charles Poole; Julian G Rosenman; Jan S Halle; Frank C Detterbeck; Thomas A Hensing; Mark A Socinski
Journal:  J Clin Oncol       Date:  2004-12-01       Impact factor: 44.544

4.  Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.

Authors:  Stein Sundstrøm; Roy M Bremnes; Stein Kaasa; Ulf Aasebø; Reidulv Hatlevoll; Ragnar Dahle; Nils Boye; Mari Wang; Tor Vigander; Jan Vilsvik; Eva Skovlund; Einar Hannisdal; Steinar Aamdal
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

5.  Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy.

Authors:  P E Postmus; H H Berendsen; N van Zandwijk; T A Splinter; J T Burghouts; W Bakker
Journal:  Eur J Cancer Clin Oncol       Date:  1987-09

Review 6.  Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice.

Authors:  Antonio Rossi; Olga Martelli; Massimo Di Maio
Journal:  Cancer Treat Rev       Date:  2012-10-18       Impact factor: 12.111

7.  Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial.

Authors:  Cécile Le Péchoux; Ariane Dunant; Suresh Senan; Aaron Wolfson; Elisabeth Quoix; Corinne Faivre-Finn; Tudor Ciuleanu; Rodrigo Arriagada; Richard Jones; Rinus Wanders; Delphine Lerouge; Agnès Laplanche
Journal:  Lancet Oncol       Date:  2009-04-20       Impact factor: 41.316

8.  Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study.

Authors:  D V Skarlos; E Samantas; P Kosmidis; G Fountzilas; M Angelidou; P Palamidas; N Mylonakis; A Provata; E Papadakis; G Klouvas
Journal:  Ann Oncol       Date:  1994-09       Impact factor: 32.976

9.  Prophylactic cranial irradiation in extensive small-cell lung cancer.

Authors:  Ben Slotman; Corinne Faivre-Finn; Gijs Kramer; Elaine Rankin; Michael Snee; Matthew Hatton; Pieter Postmus; Laurence Collette; Elena Musat; Suresh Senan
Journal:  N Engl J Med       Date:  2007-08-16       Impact factor: 91.245

10.  Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party.

Authors: 
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640
View more
  3 in total

1.  SEOM guidelines 2013: a response to the needs of Spanish oncologists.

Authors:  J J Cruz-Hernández; C A Rodríguez
Journal:  Clin Transl Oncol       Date:  2013-08-08       Impact factor: 3.405

Review 2.  Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.

Authors:  Barbara Melosky; Parneet K Cheema; Anthony Brade; Deanna McLeod; Geoffrey Liu; Paul Wheatley Price; Kevin Jao; Devin D Schellenberg; Rosalyn Juergens; Natasha Leighl; Quincy Chu
Journal:  Oncologist       Date:  2020-09-23

3.  Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.

Authors:  Jingjing Qu; Farhin Shaheed Kalyani; Qian Shen; Guangdie Yang; Tianli Cheng; Li Liu; Jianya Zhou; Jianying Zhou
Journal:  J Oncol       Date:  2022-09-26       Impact factor: 4.501
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.